S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This randomized phase II trial is studying two different schedules of dasatinib to
compare how well they work in treating patients with stage IV breast cancer that has spread
to the bone.